摘要
目的探讨利伐沙班治疗急性冠脉综合征(ACS)合并糖尿病患者的疗效及安全性。方法将100例ACS合并糖尿病患者随机分为对照组和观察组,每组50例。对照组给予皮下注射依诺肝素,观察组给予口服利伐沙班,疗程均为7 d。比较两组患者治疗后纤维蛋白原(FIB)和超敏C反应蛋白(hs-CRP)的水平,以及治疗后30 d内主要不良心血管事件及出血事件发生率。结果治疗后7 d、30 d时,观察组FIB和hs-CRP水平均低于对照组(均P<0.05);治疗后30 d内,观察组心绞痛发生率低于对照组(P<0.05),但两组患者主要不良心血管事件总发生率和出血事件发生率差异均无统计学意义(均P>0.05)。结论与依诺肝素相比,利伐沙班可以更好地降低ACS合并糖尿病患者FIB和hs-CRP水平,减少心绞痛发生率,且不增加出血事件。
Objective To investigate the efficacy and safety of rivaroxaban in acute coronary syndrome(ACS) patients complicated with diabetes mellitus. Methods One hundred ACS patients complicated with diabetes mellitus were randomly divided into control group and observation group, with 50 patients in each group. The control group was given subcutaneous injection of enoxaparin, and the observation group was orally administered rivaroxaban. The course of treatment was seven days in both groups. The levels of fibrinogen(FIB) and high-sensitivity C-reactive protein(hs-CRP) after treatment, as well as the incidence rates of major adverse cardiovascular events and bleeding events 30 days after treatment were compared between the two groups. Results Seven and 30 days after treatment, the levels of FIB and hs-CRP in the observation group were lower than those in the control group(all P<0.05);30 days after treatment, the observation group exhibited a lower incidence rate of angina pectoris than the control group(P<0.05). There was no statistically significant difference in total incidence rate of major adverse cardiovascular events or incidence rate of bleeding events between the two groups(all P>0.05). Conclusion Compared with enoxaparin, rivaroxaban can better reduce the levels of FIB and hs-CRP and decrease the incidence rate of angina pectoris in ACS patients complicated with diabetes mellitus, not increasing the occurrence of bleeding events.
作者
王秀艳
王立波
石晶
徐宗云
WANG Xiu-yan;WANG Li-bo;SHI Jing;XU Zong-yun(The First Department of Cardiology,the First Affiliated Hospital of Jiamusi University,Jiamusi 154002,China;Department of Teaching Affairs,the First Affiliated Hospital of Jiamusi University,Jiamusi 154002,China)
出处
《广西医学》
CAS
2020年第6期707-710,共4页
Guangxi Medical Journal
关键词
急性冠脉综合征
糖尿病
利伐沙班
纤维蛋白原
超敏C反应蛋白
不良心血管事件
出血风险
Acute coronary syndrome
Diabetes mellitus
Rivaroxaban
Fibrinogen
High-sensitivity C-reactive protein
Major adverse cardiovascular events
Bleeding risk
